STOCK TITAN

Iradimed Corp - IRMD STOCK NEWS

Welcome to our dedicated news page for Iradimed (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iradimed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iradimed's position in the market.

Rhea-AI Summary
IRADIMED CORPORATION (NASDAQ: IRMD) announced that its President and CEO, Roger Susi, will present at the 36th Annual Roth Conference in California. The event will feature meetings, fireside chats, and presentations by executives from 500 companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
conferences
-
Rhea-AI Summary
IRADIMED CORPORATION (IRMD) reported record revenue of $17.5 million for Q4 and $65.6 million for the full year of 2023. The company's GAAP diluted EPS was $0.36 and non-GAAP diluted EPS was $0.39 for Q4 2023, and $1.35 and $1.48 for the full year 2023. Operating income increased by 21.3% for Q4 and 28.2% for the full year, compared to the same periods in 2022. IRMD also provided financial guidance for 2024, expecting revenue of $72.0 million to $74.0 million, GAAP diluted EPS of $1.37 to $1.47, and non-GAAP diluted EPS of $1.52 to $1.62. The company's domestic sales and gross profit margin fluctuated slightly compared to the previous year. Cash flow from operations increased, and the company anticipates a cash outlay of approximately $13 million towards the development of a new facility in Orlando, FL in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
earnings
-
Rhea-AI Summary
IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2023 fourth quarter financial results on February 8, 2024. A conference call will be held at 9:00 a.m. Eastern Time on the same day to discuss the results and answer questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
earnings
Rhea-AI Summary
IRADIMED CORPORATION (NASDAQ: IRMD) reports unaudited revenue for the fourth quarter of 2023 at approximately $17.5 million, bringing the total revenue for 2023 to approximately $65.6 million, up 23% from the previous year. The company's President and CEO, Roger Susi, expressed satisfaction with the results, highlighting the continuous growth in demand for their innovative MRI-compatible medical devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary
IRADIMED CORPORATION (IRMD) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
conferences
-
Rhea-AI Summary
IRADIMED CORPORATION (NASDAQ: IRMD) announced a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend of $0.15 per share. The special and quarterly dividends are payable on January 12, 2024, to shareholders of record at the close of business on December 22, 2023. The company's strong financial performance has led to these decisions, with a total resource commitment of approximately $20M for expanding production capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
dividends
Rhea-AI Summary
IRADIMED CORPORATION (NASDAQ: IRMD) has been named on Forbes' list of America's Most Successful Small-Cap Companies for 2024. The company is a leader in innovative MRI medical devices and the sole provider of non-magnetic IV infusion pump and patient vital signs monitoring systems for use during MRI procedures. Forbes screened nearly 1,000 companies with a market value between $300 million and $2 billion to find 389 companies with positive sales growth over the past 12 months and a share price of at least $5. IRMD's inclusion in this list is a testament to its exceptional team and unwavering commitment to success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
Rhea-AI Summary
IRADIMED Corporation reports record revenue of $16.5 million for Q3 2023, with a 43% increase in operating income. The monitoring business grew by 40% compared to Q2 2023. Full-year 2023 revenue is expected to be $65.0 million to $65.5 million, with GAAP diluted EPS of $1.34 to $1.37 and non-GAAP diluted EPS of $1.48 to $1.51.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.9%
Tags
earnings
-
Rhea-AI Summary
IRADIMED Corporation to release 2023 Q3 financial results on November 3rd
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
earnings
Rhea-AI Summary
IRADIMED CORPORATION to participate in two investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
conferences
Iradimed Corp

Nasdaq:IRMD

IRMD Rankings

IRMD Stock Data

557.04M
6.54M
37.1%
51.51%
0.89%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Winter Springs

About IRMD

iradimed corporation develops, manufactures, markets, and distributes magnetic resonance imaging (mri) compatible medical devices, and related accessories and services in the united states and internationally. it offers mri compatible intravenous (iv) infusion pump system with associated disposable iv tubing sets; and mri compatible patient vital signs monitoring system. the company also provides iv poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and spo2 monitoring with sensors and accessories. it serves hospitals, acute care facilities, and outpatient imaging centers. the company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. iradimed corporation was incorporated in 1992 and is headquartered in winter springs, florida.